Home / Business and Economy / Drugmakers Eye Historic $400 Billion Combination
Drugmakers Eye Historic $400 Billion Combination
3 Aug
Summary
- AstraZeneca and Bristol Myers Squibb are in talks for a merger.
- The potential combination is valued at approximately $400 billion.
- Drug competition in oncology could hinder the merger's success.
UK drugmaker AstraZeneca has reportedly engaged in merger discussions with Bristol Myers Squibb. These talks, which have spanned several months, center on a potential combination valued at approximately $400 billion. Such a deal would position the merged entity as the fourth largest pharmaceutical company by market value globally. Both companies possess significant oncology portfolios. However, analysts note potential hurdles due to direct competition between Bristol Myers' Opdivo and AstraZeneca's Imfinzi, particularly in the non-small cell lung cancer market. The structure of any potential deal is undetermined but would likely involve a mix of cash and shares.
